FENC vs. VECT, VALN, OPT, IMTX, CGEM, RLAY, MGTX, TRML, DNA, and MAZE
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include VectivBio (VECT), Valneva (VALN), Opthea (OPT), Immatics (IMTX), Cullinan Therapeutics (CGEM), Relay Therapeutics (RLAY), MeiraGTx (MGTX), Tourmaline Bio (TRML), Ginkgo Bioworks (DNA), and Maze Therapeutics (MAZE). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals vs.
VectivBio (NASDAQ:VECT) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk, community ranking and institutional ownership.
55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 9.7% of VectivBio shares are owned by company insiders. Comparatively, 11.0% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Fennec Pharmaceuticals has a consensus price target of $13.67, indicating a potential upside of 124.78%. Given Fennec Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than VectivBio.
Fennec Pharmaceuticals received 192 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 66.67% of users gave Fennec Pharmaceuticals an outperform vote while only 43.48% of users gave VectivBio an outperform vote.
VectivBio has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500.
Fennec Pharmaceuticals has higher revenue and earnings than VectivBio.
In the previous week, Fennec Pharmaceuticals had 2 more articles in the media than VectivBio. MarketBeat recorded 2 mentions for Fennec Pharmaceuticals and 0 mentions for VectivBio. Fennec Pharmaceuticals' average media sentiment score of 1.85 beat VectivBio's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.
VectivBio has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. VectivBio's return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.
Summary
Fennec Pharmaceuticals beats VectivBio on 13 of the 17 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:FENC) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy FENC Stock Free FENC Stock Alerts